Squarepoint
STLN

Squarepoint’s Starling Oncology STLN Stock Holding History

Squarepoint’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$396K Buy
72,862
+49,031
+206% +$206K ﹤0.01% 3613
2026
Q1 		$73.2K Sell
23,831
-37,933
-61% -$116K ﹤0.01% 4111
2025
Q4 		$220K Sell
61,764
-80,790
-57% -$300K ﹤0.01% 3805
2025
Q3 		$498K Buy
+142,554
New +$488K ﹤0.01% 3238
2024
Q2 		– Sell
-105,824
Closed -$167K – 4653
2024
Q1 		$167K Buy
105,824
+8,962
+9% +$17K ﹤0.01% 3670
2023
Q4 		$198K Buy
+96,862
New +$168K ﹤0.01% 3600

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Squarepoint's STLN Position: Q2 2026 in Review

Squarepoint increased its Starling Oncology (STLN) stake by 206% in Q2 2026, buying an estimated $206K and bringing the position to 72,862 shares worth $396K. The position accounts for ﹤0.01% of the portfolio, ranked #3613.

Squarepoint first reported a position in STLN in Q4 2023 and has held it in 6 quarters since. The position peaked at $498K in Q3 2025. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Squarepoint held 72,862 shares of Starling Oncology worth $396K as of Q2 2026.
  • Squarepoint bought 49,031 Starling Oncology shares in Q2 2026, an estimated $206K.
  • Starling Oncology made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3613 holding.
  • Squarepoint first reported a position in Starling Oncology in Q4 2023 and has held it in 6 quarters since.
  • Squarepoint's Starling Oncology position peaked at $498K in Q3 2025.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.